PIK3CA and CLOVE syndrome: ,33,34,35 Recent success has been achieved using alpelisib to treat PIK3CA-associated disorders, including CLOVE syndrome (MIM: 612918); however, this is only applicable to individuals harboring a PIK3CA mutation.36